Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Kidney cancer, Renal cell cancer, Secondary cancers
Closed
Phase 1/2
The main study (KEYMAKER-U03) is looking at combinations of immunotherapy and targeted drugs for a type of kidney cancer called renal cell cancer.
Sub study 03B is part of the main study. It is open to people with a type of kidney cancer called renal cell cancer that has:
spread () or
got worse during or after treatment
Recruitment start: 15 November 2021
Recruitment end: 1 May 2023
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Balaji Venugopal
Merck Sharp & Dohme Ltd
Last reviewed: 03 Oct 2023
CRUK internal database number: 18762
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
